Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-05), Sequana Medical NV's Beta is -0.0823.
Sequana Medical NV (STU:2SE) Beta Explanation
Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.
Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
Sequana Medical NV Beta Related Terms
Sequana Medical NV Beta Historical Data
* Premium members only.
The historical data trend for Sequana Medical NV's Beta can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Sequana Medical NV's Beta, along with its competitors' market caps and Beta data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sequana Medical NV Beta vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sequana Medical NV's Beta distribution charts can be found below:
* The bar in red indicates where Sequana Medical NV's Beta falls into.
Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.
Sequana Medical NV (STU:2SE) has a Beta of -0.0823 as of Jul. 05, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Sequana Medical NV and its competitors.
Is Sequana Medical NV's Beta too high?
Sequana Medical NV's current Beta is -0.0823. Overall, Sequana Medical NV has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sequana Medical NV's Beta compare to ABT and SYK?
Sequana Medical NV's Beta of -0.0823 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Medical Devices & Instruments company?
A good Beta depends on the Medical Devices & Instruments industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Sequana Medical NV and its competitors. Sequana Medical NV's current Beta is -0.0823. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sequana Medical NV stock overvalued right now?
Based on GuruFocus' analysis, Sequana Medical NV (STU:2SE) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.19, compared to a current price of €0.51 — trading 168.9% above its estimated fair value. The current Beta is -0.0823. Sequana Medical NV's overall GF Score™ is 34/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Sequana Medical NV (STU:2SE), the current Beta is -0.0823 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sequana Medical NV (STU:2SE) Overvalued in 2026?
Based on GuruFocus' analysis, Sequana Medical NV stock appears to be overvalued.
The current stock price of €0.51 is trading 168.9% above its estimated GF Value™ of €0.19.
GuruFocus considers Sequana Medical NV to be Significantly Overvalued.
Key valuation signals for STU:2SE:
Beta: -0.0823
GF Value™: €0.19 vs. price of €0.51 (168.9% above fair value)
No single metric tells the full story. See the STU:2SE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sequana Medical NV is a commercial-stage medical device company focused on the development of treatment solutions for the management of fluid overload in liver disease, malignant ascites, and heart failure. The company's products include an alfa pump, which provides a treatment solution for the long-term management of liver refractory ascites and malignant ascites with safety, efficacy, and quality of life benefits demonstrated in multiple clinical studies. The company's geographical segments include Switzerland, Germany, the United Kingdom, France, and the Rest of the world, out of which Germany accounts for the majority of the revenue.
34GF Score
Get the complete analysis for STU:2SE
Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2SE has been successfully added to your 
